Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

HI-PRIX · Health Innovation Next Generation Payment & Pricing Models

HORIZONStatus: SIGNED1 January 202331 December 2025EU funding €3,962,458Call HORIZON-HLTH-2022-IND-13

The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementation according to the specific situation. Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use. Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI – PRIX) project are: i) to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use; ii) to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations; iii) to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders’ groups about the trade-offs between affordability, innovation and patient access. Coordinated by Bocconi University, the HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations. Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing dynamics over pharmaceutical products’ lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.

Consortium · 18 organisations

coordinator

UNIVERSITA COMMERCIALE LUIGI BOCCONI

IT · €1,241,308

associatedPartner

THE OFFICE OF HEALTH ECONOMICS

UK

associatedPartner

SERVEI CATALA DE LA SALUT

ES

associatedPartner

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

UK

associatedPartner

LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE

UK

participant

ESCUELA ANDALUZA DE SALUD PUBLICA SA

ES · €292,976

participant

HTA AUSTRIA - AUSTRIAN INSTITUTE FOR HEALTH TECHNOLOGY ASSESSMENT GMBH

AT · €318,088

participant

UNIVERSITY OF HAMBURG

DE · €453,813

participant

UNIVERSITE LIBRE DE BRUXELLES

BE · €212,798

participant

UNIVERSIDADE NOVA DE LISBOA

PT · €291,801

participant

VILNIAUS UNIVERSITETAS

LT · €89,378

participant

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

ES · €231,300

associatedPartner

AGENZIA ITALIANA DEL FARMACO

IT

thirdParty

HOSPITAL CLINIC DE BARCELONA

ES

participant

ERASMUS UNIVERSITEIT ROTTERDAM

NL · €420,375

associatedPartner

INFARMED - AUTORIDADE NACIONAL DO MEDICAMENTO E PRODUTOS DA SAUDE IP

PT

participant

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.

ES · €137,373

participant

ECOLE D'ECONOMIE DE PARIS

FR · €273,250

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.